Excellent quarter for GlaxoSmithKline

Britain-based GlaxoSmithKline today has announced a quarter exceeding analysts’ expectations, especially thanks to excellent sales performances from the new herpes vaccine, whose revenues have offset the market share loss due to Advair’s patent expiring in the US.